Paul Smart Clinical Oncology Society of Australia Annual Scientific Meeting 2023

Abstracts this author is presenting:

• AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab + Tislelizumab in Patients With Checkpoint Inhibitor (CPI)-Experienced Advanced Non-Small Cell Lung Cancer (NSCLC) — Lunch, Poster Viewing, Exhibition & COSA Group Meetings